B. Riley Upgrades MacroGenics (MGNX) to Buy Amid Sector Activity Driven by Gilead
B. Riley has upgraded MacroGenics (MGNX) to a 'Buy' rating from 'Neutral' and set a $9 price target, citing the company's position in the antibody-drug conjugate (ADC) space and recent sector activity driven by Gilead. The FDA has lifted a partial clinical hold on MacroGenics' Phase 2 LINNET trial for lorigerlimab, allowing the company to resume enrollment with updated safety measures.
Tickers: $GILD
Topics: Analyst Outlook Biotech Clinical Trials Stock Rating